Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BD's Onclarity HPV test is approved by Health Canada

What are you searching for?

Sign in
OEM News

Health Canada Approves BD’s at Home Cervical Cancer Screening Test

The BD Onclarity HPV Assay for HPV testing provides an alternative to traditional Pap tests.

Author Image

By: Rachel Klemovitch

Assistant Editor

BD has received approval from Health Canada for the BD Onclarity HPV Assay for human papillomavirus (HPV) testing for the use of self-collected vaginal specimens at home.  

This approval brings Canada one step closer to achieving the collective goal of eliminating cervical cancer by 2040 and underscores BD’s commitment to advancing women’s health.

“Self-collection is a game-changer for health equity, as it removes the logistical, financial and psychological barriers many women face when accessing traditional screening methods,” stated Ivy Parks, president of BD Canada. “By providing a convenient and reliable option for HPV testing at home, we are not only improving access to care but also empowering women to take proactive steps in managing their health. This innovation is a testament to BD’s dedication to breaking down barriers and ensuring all women, regardless of their circumstances, have the opportunity to protect themselves from cervical cancer.”

Compared to the traditional Pap test, HPV self-collection is less invasive, more cost-effective, and requires less frequent testing, now recommended every five years. The accuracy of self-collection for HPV is at the same standard as clinician-collected samples, making cervical cancer prevention more accessible, especially to remote, rural, and vulnerable populations. 

This is critical, considering cervical cancer incidence is three-fold higher in underserved populations in remote communities who have limited access to screening when compared to the general population.

BD Onclarity HPV Assay is the only Health Canada licensed test that supports self-collection with HPV extended genotyping to measure a woman’s true risk for cervical pre-cancer and cancer more precisely. 

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Add Medical Product Outsourcing as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics